Canaccord Genuity Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $113
Canaccord Genuity Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $113
Canaccord Genuity維持對intra-cellular therapies的買入評級，將目標價上調至113美元。
Canaccord Genuity analyst Sumant Kulkarni maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $107 to $113.
Canaccord Genuity分析師Sumant Kulkarni認爲Intra-cellular Therapies(NASDAQ:ITCI) 買入並將目標價從107美元上調至113美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。